Skip to main content

Specialty Pharmacy

  • FDA approves Vivitrol

    SILVER SPRING, Md. The Food and Drug Administration approved a drug to treat and prevent relapse after patients with opioid dependence have undergone detoxification treatment.

    Vivitrol is an extended-release formulation of naltrexone -- which works to block opioid receptors in the brain -- administered by intramuscular injection once a month. It only is administered by a physician.

     

  • Roche buys rights for danoprevir from InterMune

    BASEL, Switzerland Swiss drug maker Roche has bought the rights to an investigative treatment for hepatitis C, Roche said.

     

    The company announced Thursday that it had purchased global development and commercialization rights to the drug RG7227/ITMN-191 (danoprevir) from InterMune for $175 million.

     

     

    Roche said the drug had shown promise in preclinical and early clinical development. The two companies have been developing the drug since 2006.

     

  • IMS Health projects growth for Rx market

    NORWALK, Conn. The global pharmaceutical market will reach a value of $880 billion next year, according to a report by market research firm IMS Health.

     

    IMS Health forecasted 5% to 7% growth in 2011 in its annual IMS Market Prognosis, compared with 4% to 5% growth this year.

     

     

  • Amgen: Vectibix improves progression-free survival for cancer patients

    THOUSAND OAKS, Calif. An investigative biotech drug administered together with chemotherapy helped extend the lives of cancer patients without their disease getting worse, also known as progression-free survival, according to results of two clinical trials announced this week by Amgen.

     

  • HGS, Novartis halt further development of Zalbin

    ROCKVILLE, Md. Human Genome Sciences and Novartis have decided not to further develop an investigative biologic treatment for hepatitis C following the Food and Drug Administration’s decision to decline its approval, HGS said Tuesday.

     

    HGS said it received a complete response letter from the FDA concerning the drug Zalbin (albinterferon alfa-2b). The FDA delivers a complete response letter to indicate that it has finished reviewing an application, but questions remain that preclude final approval.

     

     

X
This ad will auto-close in 10 seconds